安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- HIGHLIGHTS OF PRESCRIBING INFORMATION - HALAVEN
FULL PRESCRIBING INFORMATION: CONTENTS 1 INDICATIONS AND USAGE 1 1 Metastatic Breast Cancer 1 2 Liposarcoma 2 DOSAGE AND ADMINISTRATION 2 1 Recommended Dose 2 2 Dose Modification 2 3 Instructions for Preparation and Administration 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5 1 Neutropenia
- FULL PRESCRIBING INFORMATION: CONTENTS* - Food and Drug Administration
See full prescribing information for HALAVEN HALAVEN ® (eribulin mesylate) Injection For intravenous administration Initial US Approval: 2010 -----INDICATIONS AND USAGE----- HALAVEN is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received
- Eribulin in Triple Negative Metastatic Breast Cancer: Critic . . .
Abstract Triple negative breast cancer (TNBC) is characterized by distinctive biological features that confer an aggressive clinical behavior In TNBC patients, the absence of well-defined driver pathways such as hormonal receptor expression or hyperactivation of the human epidermal growth factor receptor 2 (HER2) significantly reduce the spectrum of therapeutic options, which are currently
- Eribulin Improves Survival of Women with Metastatic Breast Cancer
Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE Based on these findings, the FDA approved eribulin last November for women with metastatic disease who have already undergone at least two previous
- Clinical outcomes of patients with metastatic breast cancer treated . . .
Background: Eribulin is a novel synthetic analog of halichondrin B that acts as a microtubule inhibitor and inhibits the G2-M growth phase Eribulin was approved for metastatic breast cancer (MBC) based on the landmark phase 3 EMBRACE trial (Cortes et al, Lancet 2011; NCT00388726); however, only a small number of Asian patients were included in that trial
- HALAVEN® (eribulin mesylate) injection, for intravenous use
effectively See full prescribing information for HALAVEN HALAVEN® (eribulin mesylate) injection, for intravenous use Initial U S Approval: 2010 INDICATIONS AND USAGE HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens
- Is HALAVEN® Right For Metastatic Breast Cancer (mBC)? | HALAVEN . . .
Is HALAVEN ® treatment for metastatic breast cancer (mBC) please see full Prescribing Information The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation
- Advances in the Management of HR+ HER2– Ultralow and -Low Metastatic . . .
T-DXd is approved for adult patients with unresectable or metastatic HER2-low breast cancer after 1 or more lines of chemotherapy based on results from the Patients were treated with SG or single-agent chemotherapy (eribulin, vinorelbine, gemcitabine, or capecitabine) Of the 543 patients, 40% were HER2 IHC 0+ and 52% were HER2 low
|
|
|